Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,076Revenue $M7,670Net Margin (%)30.4Altman Z-Score7.3
Enterprise Value $M91,570EPS $2.4Operating Margin %37.6Piotroski F-Score8
P/E(ttm)39.7Beneish M-Score-2.5Pre-tax Margin (%)35.2Higher ROA y-yY
Price/Book13.610-y EBITDA Growth Rate %--Quick Ratio4.4Cash flow > EarningsY
Price/Sales12.15-y EBITDA Growth Rate %23.1Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow33.3y-y EBITDA Growth Rate %71.3ROA % (ttm)15.3Higher Current Ratio y-yY
Dividend Yield %--PEG1.7ROE % (ttm)43.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M793ROIC % (ttm)46.7Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGRonald Muhlenkamp 2015-03-31 Reduce-0.02%$110.51 - $128.5
($119.49)
$ 116.09-3%Reduce 0.81%85,540
CELGJoel Greenblatt 2015-03-31 Add0.01%$110.51 - $128.5
($119.49)
$ 116.09-3%Add 75.33%17,987
CELGMario Gabelli 2015-03-31 Reduce$110.51 - $128.5
($119.49)
$ 116.09-3%Reduce 0.08%24,940
CELGKen Fisher 2015-03-31 Add$110.51 - $128.5
($119.49)
$ 116.09-3%Add 1.14%229,918
CELGRonald Muhlenkamp 2014-12-31 Reduce-1.03%$86.38 - $118.68
($105.53)
$ 116.0910%Reduce 41.31%86,240
CELGJoel Greenblatt 2014-12-31 Buy 0.01%$86.38 - $118.68
($105.73)
$ 116.0910%New holding10,259
CELGGeorge Soros 2014-09-30 Sold Out -0.45%$83.13 - $96.21
($90.29)
$ 116.0929%Sold Out0
CELGJoel Greenblatt 2014-09-30 Sold Out -0.07%$83.13 - $96.21
($90.29)
$ 116.0929%Sold Out0
CELGKen Fisher 2014-09-30 Add0.02%$83.13 - $96.21
($90.29)
$ 116.0929%Add 77.12%232,137
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 116.0953%Reduce 51.74%144,140
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 116.0953%New holding688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 116.0953%New holding63,980
CELGKen Fisher 2014-06-30 Add0.01%$68.45 - $86.8
($75.89)
$ 116.0953%Add 75.59%131,064
CELGRonald Muhlenkamp 2014-03-31 Add0.05%$69.645 - $85.97
($79.19)
$ 116.0947%Add 1.29%298,650
CELGKen Fisher 2014-03-31 Add0.01%$69.645 - $85.97
($79.19)
$ 116.0947%Add 1591.80%74,642
CELGMario Gabelli 2014-03-31 Reduce$69.645 - $85.97
($79.19)
$ 116.0947%Reduce 3.58%21,540
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.19)
$ 116.0947%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.245 - $85.385
($79.13)
$ 116.0947%Add 2.87%294,850
CELGMario Gabelli 2013-12-31 Add$72.245 - $85.385
($79.13)
$ 116.0947%Add 6.69%22,340
CELGKen Fisher 2013-12-31 Reduce$72.245 - $85.385
($79.13)
$ 116.0947%Reduce 11.41%4,412
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STEIN LAWRENCE VSee Remarks 2015-05-14Sell2,542$114.851.08view
KAPLAN GILLADirector 2015-02-26Sell15,000$122.89-5.53view
CASEY MICHAEL DDirector 2015-02-25Sell15,000$123.19-5.76view
KARSEN PERRY Asee remarks 2015-02-11Sell27,896$120.12-3.35view
Alles Mark JSee Remarks 2015-02-06Sell117,099$120.68-3.8view
STEIN LAWRENCE VSee Remarks 2015-01-15Sell26,666$120.01-3.27view
KAPLAN GILLADirector 2015-01-02Sell45,536$113.472.31view
Daniel Thomas Osee remarks 2014-12-15Sell30,000$115.060.9view
KAPLAN GILLADirector 2014-12-08Sell15,000$118.2-1.79view
Daniel Thomas Osee remarks 2014-11-24Sell33,818$110.275.28view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    jee's porfolio May 23 2015 
    Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 
    February Pick Of Biotech Stocks Feb 17 2015 
    Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Nov 18 2014 
    Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Coun Nov 17 2014 
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    Weekly 52-Week Highs Highlight: ALL, SRE, CLX, CELG Oct 05 2014 
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 

    More From Other Websites
    The Most Loved Biotechs of Big Hedge Funds May 23 2015
    A Beautiful Biotech Summer? May 22 2015
    Why Do Biotech Stocks Look Attractive? May 21 2015
    Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair May 21 2015
    Move Over Chip Stocks: Here Are 5 Top Biotechs May 20 2015
    Move Aside, Chip Stocks, Biotechs Are Leaders Too May 20 2015
    Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog May 19 2015
    Analysis of Phase II Data for Celgene's Investigational Oral GED-0301 in Patients with Active... May 19 2015
    Analysis of Phase II Data for Celgene’s Investigational Oral GED-0301 in Patients with Active... May 19 2015
    Celgene, Lannett Lead Boisterous Day For Drugmakers May 18 2015
    Celgene's Crohn's Disease Drug Prompts Lingering Questions May 18 2015
    FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with... May 18 2015
    FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with... May 18 2015
    Celgene, Gilead, Netflix, Costco: Jim Cramer's Views May 18 2015
    Ask anything: how can I become more consistent as a trader? May 16 2015
    Apple Inc. (AAPL), Southwest Airlines Co (LUV), McDonald’s Corporation (MCD) Among Long-Term Stock... May 15 2015
    These 5 Stocks Look Toxic for Your Portfolio in May May 15 2015
    5 Things Celgene's Management Wants You to Know May 14 2015
    Cancer data deluge May 14 2015
    Biotech: Asco Giveth, Asco Taketh Away May 14 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK